- Use of chronokines for age-associated disorders. We have demonstrated that sKL expression increases bone density, and reduces bone fragility and osteopenia, as well as it increases muscle strength, and reduces sarcopenia (paper already submited). We have also generated a new chimeric chronokine with therapeutic activity (already patented).
- Development of AAV gene therapy strategies for rare diseases affecting the CNS, such as SPG52; GNB1 Encephalopathy; MLC; ALS; Wolfram syndrome; and MPS-VII. In all cases, we closely collaborate with Patient’s Associations. During 2023, we have started to work in a new disease (ADSL Deficiency) and have demonstrated that klotho has therapeutic effects in protecting neurons and neuronal functioning in genetic diseases (patent licensed to a US company).
eCORE
- Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation
- Chronic, Prevalent Diseases & Aging
Team
Group Leader
Miguel Chillon Rodriguez
Principal Investigator (PI)
Assumpció Bosch, Beatriz Almolda
Researchers
Angela Sánchez Osuna, Joan Roig Soriano, Susana Miravet, Angel Edo
PhD Students
Sergi Verdés Franquesa, Alejandro Brao González, Rubén Guerrero Yagüe, Irina Rodríguez Reverté, Maria Page Galocha, Judith Sauleda Sauleda, Rebeca Blanch, Jon Esandi, David Ramirez; Laura Rodriguez
Lab Technicians
Javier del Rey Azpiri, Jorge Lunar Roldán, Laia Rubio, Israel Alcazar, Miriam Calles, Marc Cabrera, Elsa Ibarrola, Nerea Jimenez
Publications
Roig-Soriano, J., Sánchez-de-Diego, C., Esandi-Jauregui, J., Verdés, S., Abraham, C. R., Bosch A, Ventura, F., Chillon M
Differential toxicity profile of secreted and processed α-Klotho expression over mineral metabolism and bone microstructure
Scientific Reports, 2023. 13(1):4211
DOI: 10.1038/s41598-023-31117-6
IF: 4.6
Kagiava A, Karaiskos C, Lapathitis G, Heslegrave A, Sargiannidou I, Zettergerg H, Bosch A & Kleopa KA.
Gene replacement therapy in two Golgi-retained CMTX1 mutants before and after the onset of demyelinating neuropathy.
Mol Ther Methods Clin Dev. 2023. 30:377-393
DOI: 10.1016/j.omtm.2023.07.011
IF: 4.7
Peris M, Benseny-Cases N, Manich G, Zerpa O, Almolda B, Perálvarez-Marín À, González B, Castellano B.
Roadmap for Postnatal Brain Maturation: Changes in Gray and White Matter Composition during Development Measured by Fourier Transformed Infrared Microspectroscopy.
ACS Chem Neurosci. 2023 Sep 6;14(17):3088-3102.
DOI: 10.1021/acschemneuro.3c00237
IF: 5.0
Garcia-Segura S, Del Rey J, Closa L, Garcia-Martínez I, Hobeich C, Castel AB, Vidal F, Benet J, Oliver-Bonet M.
Characterization of Seminal Microbiome of Infertile Idiopathic Patients Using Third-Generation Sequencing Platform.
Int J Mol Sci. 2023 Apr 26;24(9):7867
DOI: 10.3390/ijms24097867
IF: 5.6
Projects
Estudio y desarrollo de la primera plataforma tecnológica de ensayos para virus adenoasociados en terápia génica
Principal Investigator: Miguel Chillon
Agency: ISCIII. CONVOCATORIA proyectos de i+d+i vinculados a la medicina personalizada y terapias avanzadas. PMPTA22/00048
Funding: 296,571€
Period: 01/04/23 - 31/03/25
Therapeutical modulation of the microglia-neuronal interaction by chronokines to treat chronic brain inflammation associated with aging. (μ−4-WELL-AGING).
Principal Investigator: Miguel Chillon
Agency: Proyectos de Generación de Conocimiento. Ministerio de Ciencia e Innovación (MICINN). (PID2022-142624OB-I00)
Funding: 125,000 €
Period: 01/09/2023 - 31/08/2026
Personalized gene therapy for MECP2 using CRISPR/Cas9 technology together with AAV administration in 3D cell cultures and Kl mice
Principal Investigator: Miguel Chillon
Agency: European Joint Programme-Rare Diseases and ISC-III EJP RD JTC 2020. AC20/00051
Funding: 169,097 €
Period: 1/1/2021 - 31/12/2023
Gene therapy to treat Megalencephalic Leukodystrophy with subcortical cysts (MLC)
Principal Investigator: Assumpcio Bosch
Agency: European Leukodystrophy Association. (ELA 2022-00412)
Funding: 189,564 €
Period: 1/3/2023 - 28/2/2025
Terapia génica para esclerosis lateral amiotrófica dirigida a estimular la neuroprotección y la modulación de la neuroinflamación
Principal Investigator: Assumpcio Bosch
Agency: Ministerio Ciencia Innovación. Plan Nacional. PID2020-116735RB-I00
Funding: 117,975 €
Period: 1/9/2021 - 30/8/2024
Patents
Klotho fusion protein and uses thereof.
Priority Number: EP23382593.4
Priority Date: 15/6/2023
Applicants: 11,66% VHIR; 14,16% ICREA; 74,12% UAB
